Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Curran, Kevin J  [Clear All Filters]
2023
Tamari R, Scordo M, Kunvarjee B, Proli A, Lin A, Flynn JR, Cho C, Devlin SM, Klein E, Boulad F, et al. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation. Blood Adv. 2023.
Kunvarjee B, Bidgoli A, Madan RPellett, Vidal E, McAvoy D, Hosszu KK, Scaradavou A, Spitzer BG, Curran KJ, Cancio M, et al. Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations. J Allergy Clin Immunol. 2023.
Lucas AGTroullio, Boelens JJan, Prockop SE, Curran KJ, Bresters D, Kollen W, Versluys B, Bierings MB, Archer A, Davis E, et al. Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients. Front Oncol. 2023;13:1221782.
Eylon M, Prabhu S, John S, King MJM, Bhatt D, Curran KJ, Erickson C, Karras NA, Phillips CL, Satwani P, et al. Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023;14:1239132.
Satty AM, Klein E, Mauguen A, Kunvarjee B, Boelens JJan, Cancio M, Curran KJ, Kernan NA, Prockop SE, Scaradavou A, et al. T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML. Bone Marrow Transplant. 2023.
Prockop SE, Hasan AN, Doubrovina E, Dahi PB, M Rodriguez-Sanchez I, Curry M, Mauguen A, Papanicolaou GA, Su Y, Yao JJ, et al. Third party CMV viral specific T-cells for refractory CMV viremia and disease after hematopoietic transplant. J Clin Invest. 2023.
Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano J-A, et al. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023;65:102268.